Market Cap : 70.79 B | Enterprise Value : 80.27 B | P/E (TTM) : 28.07 | P/B : 2.60 |
---|
DHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
vs
industry |
vs
history |
||
---|---|---|---|
Cash-to-Debt | 0.10 |
95% of the 261 Companies in the Global Diagnostics & Research industry. ( Industry Median: 3.52 vs. DHR: 0.10 ) Ranked among companies with meaningful Cash-to-Debt only. |
DHR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.15 Max: 1.33 Current: 0.1 |
Equity-to-Asset | 0.58 |
58% of the 239 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.61 vs. DHR: 0.58 ) Ranked among companies with meaningful Equity-to-Asset only. |
DHR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27 Med: 0.51 Max: 0.67 Current: 0.58 |
Debt-to-Equity | 0.39 |
53% of the 164 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.36 vs. DHR: 0.39 ) Ranked among companies with meaningful Debt-to-Equity only. |
DHR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13 Med: 0.36 Max: 1.6 Current: 0.39 |
Debt-to-EBITDA | 2.35 |
59% of the 116 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.77 vs. DHR: 2.35 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
DHR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.79 Med: 1.44 Max: 4.21 Current: 2.35 |
Interest Coverage | 19.44 |
60% of the 163 Companies in the Global Diagnostics & Research industry. ( Industry Median: 76.01 vs. DHR: 19.44 ) Ranked among companies with meaningful Interest Coverage only. |
DHR'
s Interest Coverage Range Over the Past 10 Years
Min: 12.58 Med: 17.66 Max: 22.1 Current: 19.44 |
Piotroski F-Score: 7 |
|
Altman Z-Score: 3.52 |
|
Beneish M-Score: -2.52 |
|
WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
vs
industry |
vs
history |
||
---|---|---|---|
Operating Margin % | 16.69 |
85% of the 242 Companies in the Global Diagnostics & Research industry. ( Industry Median: -0.59 vs. DHR: 16.69 ) Ranked among companies with meaningful Operating Margin % only. |
DHR'
s Operating Margin % Range Over the Past 10 Years
Min: 13.79 Med: 16.02 Max: 17.07 Current: 16.69 |
Net Margin % | 13.56 |
88% of the 241 Companies in the Global Diagnostics & Research industry. ( Industry Median: -2.48 vs. DHR: 13.56 ) Ranked among companies with meaningful Net Margin % only. |
DHR'
s Net Margin % Range Over the Past 10 Years
Min: 10.3 Med: 13.95 Max: 23.26 Current: 13.56 |
ROE % | 10.03 |
70% of the 242 Companies in the Global Diagnostics & Research industry. ( Industry Median: -6.75 vs. DHR: 10.03 ) Ranked among companies with meaningful ROE % only. |
DHR'
s ROE % Range Over the Past 10 Years
Min: 10.1 Med: 13.17 Max: 14.27 Current: 10.03 |
ROA % | 5.54 |
75% of the 262 Companies in the Global Diagnostics & Research industry. ( Industry Median: -4.54 vs. DHR: 5.54 ) Ranked among companies with meaningful ROA % only. |
DHR'
s ROA % Range Over the Past 10 Years
Min: 5.42 Med: 7.58 Max: 8.58 Current: 5.54 |
ROC (Joel Greenblatt) % | 80.18 |
90% of the 259 Companies in the Global Diagnostics & Research industry. ( Industry Median: -9.57 vs. DHR: 80.18 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
DHR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.73 Med: 80.59 Max: 118.82 Current: 80.18 |
3-Year Revenue Growth Rate | 13.00 |
69% of the 182 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.80 vs. DHR: 13.00 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
DHR'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7 Med: 10.1 Max: 47.6 Current: 13 |
3-Year EBITDA Growth Rate | 14.90 |
61% of the 178 Companies in the Global Diagnostics & Research industry. ( Industry Median: 10.10 vs. DHR: 14.90 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
DHR'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21.1 Med: 14.9 Max: 51.5 Current: 14.9 |
3-Year EPS without NRI Growth Rate | 15.20 |
60% of the 163 Companies in the Global Diagnostics & Research industry. ( Industry Median: 10.10 vs. DHR: 15.20 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
DHR'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7 Med: 14.7 Max: 92 Current: 15.2 |
Caxton Associates 7,300 sh (New) Ray Dalio 16,638 sh (New) Louis Moore Bacon 125,201 sh (+222.84%) Robert Olstein 65,000 sh (+18.18%) Ken Fisher 5,224 sh (+1.89%) | Chuck Akre 1,655,300 sh (unchged) John Hussman 30,000 sh (unchged) John Griffin 1,760,000 sh (unchged) | Jeremy Grantham Sold Out Steven Cohen Sold Out Paul Tudor Jones Sold Out Dodge & Cox 5,099,223 sh (-2.34%) Ruane Cunniff 1,664,622 sh (-3.96%) Murray Stahl 34,135 sh (-4.08%) Jim Simons 1,459,300 sh (-4.13%) Mario Gabelli 10,696 sh (-4.47%) Daniel Loeb 3,100,000 sh (-4.62%) First Eagle Investment 2,623,552 sh (-16.90%) Joel Greenblatt 269,309 sh (-35.99%) |
Paul Tudor Jones 30,918 sh (New) Steven Cohen 697,114 sh (New) Louis Moore Bacon 214,900 sh (+71.64%) Jim Simons 1,697,400 sh (+16.32%) First Eagle Investment 2,925,603 sh (+11.51%) Daniel Loeb 3,300,000 sh (+6.45%) Ken Fisher 5,423 sh (+3.81%) Dodge & Cox 5,250,773 sh (+2.97%) | Robert Olstein 65,000 sh (unchged) Chuck Akre 1,655,300 sh (unchged) | John Hussman Sold Out Ray Dalio Sold Out Joel Greenblatt Sold Out Mario Gabelli 10,616 sh (-0.75%) Ruane Cunniff 1,648,054 sh (-1.00%) Murray Stahl 33,664 sh (-1.38%) Caxton Associates 7,100 sh (-2.74%) John Griffin 1,487,700 sh (-15.47%) |
Arnold Van Den Berg 100,650 sh (New) Wallace Weitz 209,870 sh (New) Ray Dalio 18,745 sh (New) Joel Greenblatt 26,710 sh (New) MS Global Franchise Fund 116,462 sh (New) Signature Select Canadian Fund 67,416 sh (New) Eaton Vance Worldwide Health Sciences Fund 291,350 sh (New) Steven Cohen 2,626,865 sh (+276.82%) | Daniel Loeb 3,300,000 sh (unchged) Chuck Akre 1,655,300 sh (unchged) | Ruane Cunniff Sold Out Caxton Associates Sold Out Dodge & Cox 5,217,123 sh (-0.64%) Mario Gabelli 10,305 sh (-2.93%) Robert Olstein 63,000 sh (-3.08%) Ken Fisher 5,145 sh (-5.13%) Murray Stahl 28,908 sh (-14.13%) Paul Tudor Jones 26,169 sh (-15.36%) Louis Moore Bacon 178,395 sh (-16.99%) John Griffin 1,124,700 sh (-24.40%) First Eagle Investment 1,568,751 sh (-46.38%) Jim Simons 96,300 sh (-94.33%) |
Vanguard Health Care Fund 3,798,100 sh (New) Pioneer Investments 642,562 sh (New) Tom Russo 1,400 sh (New) Jim Simons 1,149,900 sh (+1094.08%) Joel Greenblatt 127,041 sh (+375.63%) MS Global Franchise Fund 171,229 sh (+47.03%) Wallace Weitz 239,870 sh (+14.29%) Ken Fisher 5,560 sh (+8.07%) Daniel Loeb 3,310,000 sh (+0.30%) | Chuck Akre 1,655,300 sh (unchged) Eaton Vance Worldwide Health Sciences Fund 291,350 sh (unchged) | First Eagle Investment Sold Out Ray Dalio Sold Out Paul Tudor Jones Sold Out Dodge & Cox 5,192,223 sh (-0.48%) Arnold Van Den Berg 98,955 sh (-1.68%) Mario Gabelli 9,965 sh (-3.30%) Robert Olstein 54,000 sh (-14.29%) Louis Moore Bacon 136,482 sh (-23.49%) Murray Stahl 21,488 sh (-25.67%) John Griffin 720,000 sh (-35.98%) Steven Cohen 281,112 sh (-89.30%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
---|---|---|---|---|---|---|---|---|
Dodge & Cox | 2017-12-31 | Reduce -0.48% | $85.26 - $94.62 | $ 101.34 | 11% | 5,192,223 | ![]() | |
Vanguard Health Care Fund | 2017-12-31 | New Buy | 0.77% | $85.26 - $94.62 | $ 101.34 | 11% | 3,798,100 | ![]() |
Wallace Weitz | 2017-12-31 | Add 14.29% | 0.12% | $85.26 - $94.62 | $ 101.34 | 11% | 239,870 | ![]() |
Joel Greenblatt | 2017-12-31 | Add 375.63% | 0.13% | $85.26 - $94.62 | $ 101.34 | 11% | 127,041 | ![]() |
Arnold Van Den Berg | 2017-12-31 | Reduce -1.68% | 0.02% | $85.26 - $94.62 | $ 101.34 | 11% | 98,955 | ![]() |
Robert Olstein | 2017-12-31 | Reduce -14.29% | 0.1% | $85.26 - $94.62 | $ 101.34 | 11% | 54,000 | ![]() |
Mario Gabelli | 2017-12-31 | Reduce -3.30% | $85.26 - $94.62 | $ 101.34 | 11% | 9,965 | ![]() | |
Ken Fisher | 2017-12-31 | Add 8.07% | $85.26 - $94.62 | $ 101.34 | 11% | 5,560 | ![]() | |
First Eagle Investment | 2017-12-31 | Sold Out | 0.3% | $85.26 - $94.62 | $ 101.34 | 11% | 0 | ![]() |
Dodge & Cox | 2017-09-30 | Reduce -0.64% | $79.29 - $88.45 | $ 101.34 | 21% | 5,217,123 | ![]() | |
First Eagle Investment | 2017-09-30 | Reduce -46.38% | 0.27% | $79.29 - $88.45 | $ 101.34 | 21% | 1,568,751 | ![]() |
Wallace Weitz | 2017-09-30 | New Buy | 0.76% | $79.29 - $88.45 | $ 101.34 | 21% | 209,870 | ![]() |
Arnold Van Den Berg | 2017-09-30 | New Buy | 1.21% | $79.29 - $88.45 | $ 101.34 | 21% | 100,650 | ![]() |
Robert Olstein | 2017-09-30 | Reduce -3.08% | 0.02% | $79.29 - $88.45 | $ 101.34 | 21% | 63,000 | ![]() |
Joel Greenblatt | 2017-09-30 | New Buy | 0.03% | $79.29 - $88.45 | $ 101.34 | 21% | 26,710 | ![]() |
Mario Gabelli | 2017-09-30 | Reduce -2.93% | $79.29 - $88.45 | $ 101.34 | 21% | 10,305 | ![]() | |
Ken Fisher | 2017-09-30 | Reduce -5.13% | $79.29 - $88.45 | $ 101.34 | 21% | 5,145 | ![]() | |
Ruane Cunniff | 2017-09-30 | Sold Out | 1.29% | $79.29 - $88.45 | $ 101.34 | 21% | 0 | ![]() |
Dodge & Cox | 2017-06-30 | Add 2.97% | 0.01% | $81.7 - $86.84 | $ 101.34 | 20% | 5,250,773 | ![]() |
First Eagle Investment | 2017-06-30 | Add 11.51% | 0.06% | $81.7 - $86.84 | $ 101.34 | 20% | 2,925,603 | ![]() |
Ruane Cunniff | 2017-06-30 | Reduce -1.00% | 0.01% | $81.7 - $86.84 | $ 101.34 | 20% | 1,648,054 | ![]() |
Mario Gabelli | 2017-06-30 | Reduce -0.75% | $81.7 - $86.84 | $ 101.34 | 20% | 10,616 | ![]() | |
Ken Fisher | 2017-06-30 | Add 3.81% | $81.7 - $86.84 | $ 101.34 | 20% | 5,423 | ![]() | |
Joel Greenblatt | 2017-06-30 | Sold Out | 0.29% | $81.7 - $86.84 | $ 101.34 | 20% | 0 | ![]() |
Industry: | Medical Diagnostics & Research » Diagnostics & Research NAICS: 621511 SIC: 8071 | |
---|---|---|
Compare: | NYSE:TMO, XAMS:PHIA, NYSE:A, NYSE:IQV, TSE:6869, XSWX:LONN, NAS:IDXX, NYSE:LH, NYSE:DGX, XPAR:ERF, SZSE:300676, XTER:SRT3, XPAR:BIM, NYSE:PKI, NYSE:BIO, NYSE:QGEN, NAS:ICLR, NAS:DXCM, XTER:AFX, NAS:PRAH » details | |
Traded in other countries: | DHER34.Brazil, DAP.Germany, DHR.Mexico, DHR.Switzerland, 0R2B.UK, | |
Headquarter Location: | USA |
vs
industry |
vs
history |
||
---|---|---|---|
PE Ratio | 28.07 |
60% of the 113 Companies in the Global Diagnostics & Research industry. ( Industry Median: 35.00 vs. DHR: 28.07 ) Ranked among companies with meaningful PE Ratio only. |
DHR'
s PE Ratio Range Over the Past 10 Years
Min: 9.61 Med: 14.69 Max: 29.41 Current: 28.07 |
Forward PE Ratio | 23.15 |
53% of the 40 Companies in the Global Diagnostics & Research industry. ( Industry Median: 9999.00 vs. DHR: 23.15 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
PE Ratio without NRI | 28.07 |
60% of the 113 Companies in the Global Diagnostics & Research industry. ( Industry Median: 35.56 vs. DHR: 28.07 ) Ranked among companies with meaningful PE Ratio without NRI only. |
DHR'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.66 Med: 15.77 Max: 38.03 Current: 28.07 |
PB Ratio | 2.60 |
70% of the 245 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.02 vs. DHR: 2.60 ) Ranked among companies with meaningful PB Ratio only. |
DHR'
s PB Ratio Range Over the Past 10 Years
Min: 1.19 Med: 1.84 Max: 2.74 Current: 2.6 |
PS Ratio | 3.81 |
53% of the 230 Companies in the Global Diagnostics & Research industry. ( Industry Median: 3.81 vs. DHR: 3.81 ) Ranked among companies with meaningful PS Ratio only. |
DHR'
s PS Ratio Range Over the Past 10 Years
Min: 1.01 Med: 1.94 Max: 4.35 Current: 3.81 |
Price-to-Free-Cash-Flow | 22.76 |
59% of the 80 Companies in the Global Diagnostics & Research industry. ( Industry Median: 29.22 vs. DHR: 22.76 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
DHR'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.59 Med: 13.29 Max: 25.64 Current: 22.76 |
Price-to-Operating-Cash-Flow | 19.12 |
51% of the 97 Companies in the Global Diagnostics & Research industry. ( Industry Median: 19.94 vs. DHR: 19.12 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
DHR'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.81 Med: 11.53 Max: 21.07 Current: 19.12 |
EV-to-EBIT | 24.86 |
55% of the 118 Companies in the Global Diagnostics & Research industry. ( Industry Median: 25.06 vs. DHR: 24.86 ) Ranked among companies with meaningful EV-to-EBIT only. |
DHR'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8 Med: 12.5 Max: 35.6 Current: 24.86 |
EV-to-EBITDA | 17.91 |
55% of the 132 Companies in the Global Diagnostics & Research industry. ( Industry Median: 20.75 vs. DHR: 17.91 ) Ranked among companies with meaningful EV-to-EBITDA only. |
DHR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7 Med: 10.3 Max: 26.1 Current: 17.91 |
EV-to-Revenue | 4.27 |
52% of the 242 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.24 vs. DHR: 4.27 ) Ranked among companies with meaningful EV-to-Revenue only. |
DHR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2 Med: 2.1 Max: 5.4 Current: 4.27 |
PEG Ratio | 46.83 |
98% of the 48 Companies in the Global Diagnostics & Research industry. ( Industry Median: 3.26 vs. DHR: 46.83 ) Ranked among companies with meaningful PEG Ratio only. |
DHR'
s PEG Ratio Range Over the Past 10 Years
Min: 0.55 Med: 1.11 Max: 218.45 Current: 46.83 |
Shiller PE Ratio | 28.93 |
77% of the 39 Companies in the Global Diagnostics & Research industry. ( Industry Median: 52.49 vs. DHR: 28.93 ) Ranked among companies with meaningful Shiller PE Ratio only. |
DHR'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.2 Med: 22.71 Max: 32.9 Current: 28.93 |
Current Ratio | 1.59 |
76% of the 250 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.58 vs. DHR: 1.59 ) Ranked among companies with meaningful Current Ratio only. |
DHR'
s Current Ratio Range Over the Past 10 Years
Min: 0.9 Med: 1.43 Max: 2.23 Current: 1.59 |
Quick Ratio | 1.15 |
80% of the 250 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.14 vs. DHR: 1.15 ) Ranked among companies with meaningful Quick Ratio only. |
DHR'
s Quick Ratio Range Over the Past 10 Years
Min: 0.56 Med: 0.98 Max: 1.82 Current: 1.15 |
Days Inventory | 81.08 |
50% of the 204 Companies in the Global Diagnostics & Research industry. ( Industry Median: 79.76 vs. DHR: 81.08 ) Ranked among companies with meaningful Days Inventory only. |
DHR'
s Days Inventory Range Over the Past 10 Years
Min: 63.09 Med: 73.79 Max: 108.16 Current: 81.08 |
Days Sales Outstanding | 63.43 |
53% of the 204 Companies in the Global Diagnostics & Research industry. ( Industry Median: 67.51 vs. DHR: 63.43 ) Ranked among companies with meaningful Days Sales Outstanding only. |
DHR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.46 Med: 68.9 Max: 97.75 Current: 63.43 |
Days Payable | 69.29 |
53% of the 187 Companies in the Global Diagnostics & Research industry. ( Industry Median: 63.34 vs. DHR: 69.29 ) Ranked among companies with meaningful Days Payable only. |
DHR'
s Days Payable Range Over the Past 10 Years
Min: 59.9 Med: 69.77 Max: 110.7 Current: 69.29 |
vs
industry |
vs
history |
||
---|---|---|---|
Dividend Yield % | 0.57 |
67% of the 121 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.81 vs. DHR: 0.57 ) Ranked among companies with meaningful Dividend Yield % only. |
DHR'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.15 Med: 0.26 Max: 0.84 Current: 0.57 |
Dividend Payout Ratio | 0.16 |
80% of the 70 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.32 vs. DHR: 0.16 ) Ranked among companies with meaningful Dividend Payout Ratio only. |
DHR'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.04 Max: 0.22 Current: 0.16 |
3-Year Dividend Growth Rate | 11.90 |
61% of the 36 Companies in the Global Diagnostics & Research industry. ( Industry Median: 9.90 vs. DHR: 11.90 ) Ranked among companies with meaningful 3-Year Dividend Growth Rate only. |
DHR'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0 Med: 13.2 Max: 78.6 Current: 11.9 |
Forward Dividend Yield % | 0.63 |
66% of the 113 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.10 vs. DHR: 0.63 ) Ranked among companies with meaningful Forward Dividend Yield % only. |
N/A |
5-Year Yield-on-Cost % | 4.30 |
92% of the 142 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.41 vs. DHR: 4.30 ) Ranked among companies with meaningful 5-Year Yield-on-Cost % only. |
DHR'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.13 Med: 1.96 Max: 6.34 Current: 4.3 |
3-Year Average Share Buyback Ratio | 0.40 |
90% of the 180 Companies in the Global Diagnostics & Research industry. ( Industry Median: -7.90 vs. DHR: 0.40 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
DHR'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7 Med: -1.5 Max: 0.4 Current: 0.4 |
vs
industry |
vs
history |
||
---|---|---|---|
Earnings Yield (Greenblatt) % | 4.02 |
76% of the 265 Companies in the Global Diagnostics & Research industry. ( Industry Median: -0.98 vs. DHR: 4.02 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
DHR'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8 Med: 8 Max: 12.5 Current: 4.02 |
Forward Rate of Return (Yacktman) % | 3.80 |
69% of the 70 Companies in the Global Diagnostics & Research industry. ( Industry Median: 8.45 vs. DHR: 3.80 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. |
DHR'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.1 Med: 18.1 Max: 27.6 Current: 3.8 |
Revenue (TTM) (Mil) $ | 18,819.40 |
---|---|
EPS (TTM) $ | 3.61 |
Beta | 1.01 |
Volatility | 13.92% |
52-Week Range $ | 78.97 - 104.82 |
Shares Outstanding (Mil) | 698.57 |
Dec18 | Dec19 | Dec20 | |
---|---|---|---|
Revenue (Mil $) | 19,459 | 20,386 | 21,199 |
EBIT (Mil $) | 3,416 | 3,744 | 3,943 |
EBITDA (Mil $) | 4,754 | 5,096 | 5,194 |
EPS ($) | 4.38 | 4.73 | 4.95 |
EPS without NRI ($) | 4.38 | 4.73 | 4.95 |
EPS Growth Rate (Future 3Y To 5Y Estimate) | 10.89% | ||
Dividends per Share ($) | 0.64 | 0.69 | 0.79 |
|
Honeywell (HON) Q1 Earnings Beat on Solid Top-Line Growth Apr 20 2018 - ZACKS |
What's in the Offing for 3M Company (MMM) in Q1 Earnings? Apr 20 2018 - ZACKS |
GF Chat